Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 10/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4075603 | 0.92 | LMNA (0.52) | LMNATSHRALOX12HTTNPSR1 | |
| SCHEMBL24454992 | 0.90 | CNR2 (0.40) | LMNATSHRALOX12HTTNPSR1 | |
| SCHEMBL23912846 | 0.87 | FAAH (0.43) | FAAH | |
| SCHEMBL4182413 | 0.84 | LMNA (0.51) | LMNATSHRALOX12HTTNPSR1 | |
| SCHEMBL4182411 | 0.84 | LMNA (0.51) | LMNATSHRALOX12HTTNPSR1 | |
| SCHEMBL4080235 | 0.84 | FAAH (0.42) | LMNATSHRALOX12HTTNPSR1 | |
| SCHEMBL24454997 | 0.84 | CNR2 (0.44) | LMNATSHRALOX12HTTNPSR1 | |
| SCHEMBL4084625 | 0.81 | CNR2 (0.47) | LMNATSHRALOX12HTTNPSR1 | |
| SCHEMBL23912854 | 0.81 | FAAH (0.40) | LMNATSHRALOX12HTTNPSR1 | |
| SCHEMBL4189090 | 0.80 | FAAH (0.64) | FAAHCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022109043-A1 | FORMULATIONS AND METHODS FOR TREATING ACUTE CANNABINOID OVERDOSE | ANEBULO PHARMACEUTICALS, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-11141404-B1 | Formulations and methods for treating acute cannabinoid overdose | ANEBULO PHARMACEUTICALS, INC. (US) | 2021-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11141404-B1 | Formulations and methods for treating acute cannabinoid overdose | CNR1, CNR2, FAAH | LMNA 2773/4885TSHR 1458/4885ALOX12 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.